Terms: = Ovarian cancer AND MITF, WS2A, ENSG00000187098, 4286
12 results:
1. Divergent Malignant Melanocytic Differentiation in ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia.
Xu J; Weisman PS
Int J Gynecol Pathol; 2024 May; 43(3):302-307. PubMed ID: 37922945
[TBL] [Abstract] [Full Text] [Related]
2. Pre-treatment sarcopenic assessments as a prognostic factor for gynaecology cancer outcomes: systematic review and meta-analysis.
Sutton EH; Plyta M; Fragkos K; Di Caro S
Eur J Clin Nutr; 2022 Nov; 76(11):1513-1527. PubMed ID: 35194194
[TBL] [Abstract] [Full Text] [Related]
3. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract] [Full Text] [Related]
4. Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of ovarian cancer.
Kitami K; Yoshihara M; Koya Y; Sugiyama M; Iyoshi S; Uno K; Mogi K; Tano S; Fujimoto H; Nawa A; Kikkawa F; Kajiyama H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371469
[TBL] [Abstract] [Full Text] [Related]
5. Gene of the month: TFE 3.
Pinto K; Chetty R
J Clin Pathol; 2020 Nov; 73(11):691-694. PubMed ID: 32820043
[TBL] [Abstract] [Full Text] [Related]
6. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers.
Osmanbeyoglu HU; Shimizu F; Rynne-Vidal A; Alonso-Curbelo D; Chen HA; Wen HY; Yeung TL; Jelinic P; Razavi P; Lowe SW; Mok SC; Chiosis G; Levine DA; Leslie CS
Nat Commun; 2019 Sep; 10(1):4369. PubMed ID: 31554806
[TBL] [Abstract] [Full Text] [Related]
7. Proteomic Profiling of Iron-Treated ovarian Cells Identifies AKT Activation that Modulates the CLEAR Network.
Rockfield S; Guergues J; Rehman N; Smith A; Bauckman KA; Stevens SM; Nanjundan M
Proteomics; 2018 Dec; 18(23):e1800244. PubMed ID: 30267477
[TBL] [Abstract] [Full Text] [Related]
8. Identification, genetic testing, and management of hereditary melanoma.
Leachman SA; Lucero OM; Sampson JE; Cassidy P; Bruno W; Queirolo P; Ghiorzo P
Cancer Metastasis Rev; 2017 Mar; 36(1):77-90. PubMed ID: 28283772
[TBL] [Abstract] [Full Text] [Related]
9. Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex.
Rabban JT; Firetag B; Sangoi AR; Post MD; Zaloudek CJ
Am J Surg Pathol; 2015 Aug; 39(8):1015-25. PubMed ID: 25786086
[TBL] [Abstract] [Full Text] [Related]
10. Melanotic Xp11 translocation renal cancer: report of a case with a unique intratumoral sarcoid-like reaction.
Ritterhouse LL; Cykowski MD; Hassell LA; Slobodov G; Bane BL
Diagn Pathol; 2014 Apr; 9():81. PubMed ID: 24735727
[TBL] [Abstract] [Full Text] [Related]
11. mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma.
Wang Y; Radfar S; Liu S; Riker AI; Khong HT
BMC Med; 2010 Feb; 8():14. PubMed ID: 20163701
[TBL] [Abstract] [Full Text] [Related]
12. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
Gupta D; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2004 Jun; 28(6):771-80. PubMed ID: 15166669
[TBL] [Abstract] [Full Text] [Related]
